NCT01582568View on ClinicalTrials.gov

EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment

TerminatedOBSERVATIONAL
Enrollment

1

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions
Crohns Disease
Interventions
DRUG

Certolizumab

Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.

Trial Locations (1)

77030

Baylor College of Medicine, Houston

Sponsors

Collaborators (1)

UCB Pharma
All Listed Sponsors
collaborator

UCB Pharma

INDUSTRY

lead

Baylor College of Medicine

OTHER